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Abstract
Traditional methods of measuring magnetization in magnetic fluid samples, such as vibrating
sample magnetometry (VSM), are typically limited to maximum field strengths of about 1 T. This
work demonstrates the ability of MRI to measure the magnetization associated with two
commercial MRI contrast agents at 3 T by comparing analytical solutions to experimental imaging
results for the field pattern associated with agents in cylindrical vials. The results of the VSM and
fitted MRI data match closely. The method represents an improvement over VSM measurements
since results are attainable at imaging field strengths. The agents investigated are Feridex, a
superparamagnetic iron oxide suspension used primarily for liver imaging, and Magnevist, a
paramagnetic, gadolinium-based compound used for tumors, inflammation and vascular lesions.
MR imaging of the agents took place in sealed cylindrical vials in the presence of a surrounding
volume of deionized water where the effects of the contrast agents had a measurable effect on the
water's magnetization in the vicinity of the compartment of contrast agent. A pair of phase images
were used to reconstruct a B0 fieldmap. The resultant B0 maps in the water region, corrected for
shimming and container edge effects, were used to predict the agent's magnetization at 3 T. The
results were compared with the results from VSM measurements up to 1.2 T and close correlation
was observed. The technique should be of interest to those seeking quantification of the
magnetization associated with magnetic suspensions beyond the traditional scope of VSM. The
magnetization needs to be sufficiently strong (Ms≳50 Am2/kg Fe for Feridex and χm≳5 × 10−5 m3/
kg Gd for Magnevist) for a measurable dipole field in the surrounding water. For this reason, the
technique is mostly suitable for undiluted agents.
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INTRODUCTION
The goal of this work was to demonstrate the ability of MRI to accurately measure the
magnetization associated with two commercial MRI contrast agents. These agents were
Feridex (AMAG Pharmaceuticals, Cambridge, MA), a superparamagnetic iron oxide
suspension used primarily for liver imaging and increasingly for cell-labeling applications
(1,2,3,4,5) and Magnevist (Bayer HealthCare AG, Leverkausen, Germany) (6,7,8), a
paramagnetic, gadolinium-based (Gd) compound used in a wide variety of tumor and lesion
imaging applications.
The investigations used two distinct methods to measure magnetization: vibrating sample
magnetometry (VSM) and MRI. VSM measures the sample's magnetization by moving the
sample back and forth at high speed, creating a periodically and rapidly changing magnetic
field. This changing field is sensed by a set of pick-up coils where the induced coil voltage,
as given by Faraday's law of electromagnetic induction, is proportional to the sample's
magnetization. While high field VSM platforms exist (e.g., the EV11 system from ADE
Magnetics has a 3.1 T maximum field), cost considerations will generally limit VSM use
among the MRI community to small samples at fields ≤1 T, well below fields currently
typical in MRI (e.g., 3 T).
This method comes in the wake of measurements of magnetic susceptibility of gadolinium
contrast agents and blood susceptibility conducted by Weisskoff (11). Jung (12) also made
preliminary measurements of the magnetization associated with both Gd-DPTA (now
commercially available as Magnevist) and Ferumoxide suspensions (now commercially
available as Feridex). Neither investigation examined magnetization at 3 T or used
commercially available agents. Chu et al. (13) has described the theoretical “bulk magnetic
susceptibility shift” due to an infinite cylinder of finite wall thickness in two field
orientations (parallel and perpendicular to B0). In fact, the “susceptibility shift” refers to the
change in the local magnetic field in the region immediately surrounding a paramagnetic
species. Bowen et al. (14) have provided a thorough investigation of superparamagnetic
iron-oxide loaded cells at 1.89 T by comparing experimental results with the theoretical
predictions of Chu (13) for infinitely long cylindrical vessels of magnetic fluid. More
recently, focus has switched to the applications in susceptibility weighted imaging in vivo
although the technique is broadly similar to that employed here (15,16).
This work proposes an effective method for predicting the magnetization of Feridex and
Magnevist contrast agents using MRI. The experiments are conducted at 3 T but the method
could be equally applied at any field strength. The experimental results (both MRI and VSM
[vibrating sample magnetometry]) are compared with exact theoretical predictions for
infinite length cylinders to correlate the magnetization associated with the samples of
Feridex and Magnevist. Close correspondence is observed between the MRI results, results
from VSM measurements at 1.2 T and previously published results (11). This technique
represents an advancement over prior work in three important respects; (i) it represents the
first investigations of commercially available MRI agents, Feridex and Magnevist, (ii) the
investigations are the first conducted at 3 T and (iii) the exact rather than an approximate
solution (13,14) for infinite length cylinders is employed.
EXPERIMENTAL
VSM measurements
To examine magnetic saturation effects in a commercial SPIO particle (small iron oxide)
contrast agent, 0.0703 cc of Feridex MRI contrast agent was placed in a vibrating sample
magnetometer (Model 1660, ADE Magnetics, Westwood, MA) and the magnetic moment
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was measured. The contrast agents were examined in their undiluted states (i.e., as provided
by the manufacturers (2,6)). To account for magnetization effects due to the sample cup, a
second VSM measurement was conducted in the absence of the contrast agent with an
empty cup and the resulting magnetization was subtracted from the result in the presence of
the agent. The contrast agents' magnetizations are shown in Figure 1(a) where the units of
magnetic moment are given as Am2/kg of Fe. Feridex is a superparamagnetic agent which
saturates at high field. The saturation magnetization of the agent was estimated to be in the
region of 82 Am2/kg Fe. Feridex has a nominal density of 11.2 mg Fe/ml and and the
recommended dosage is 0.56 mg Fe/kg of bodyweight (2). A similar procedure was
employed for a 0.07266 cc sample of Magnevist contrast agent. Magnevist is a paramagnetic
agent which exhibits a linear magnetic susceptibility up to DC fields of 50 T (9). It consists
of a complex chemical formulation, supplied in concentrations containing 469.01 mg
gadopentetate dimeglumine per ml Magnevist (6). The recommended dosage is 0.2 ml per
kg bodyweight. The mass susceptibility, χm, was estimated by a linear curve fit to be
2.06×10−6 m3/kg Gd from the VSM measurements shown in Figure 1(b). Again, there was
no available data beyond 1.2 T. The two VSM measurements took on the order of 1 hour
(determined by the iteration step in field strength) to complete without additional
postprocessing of the results to determine the magnetic moment per unit volume. Repeated
experiments might improve accuracy by adding error bars but this was not attempted.
MRI measurements
In order to estimate the magnetization in MRI, B0 maps were obtained in a 3 T Siemens Trio
MRI. The agent was placed in a long, narrow NMR tube (Bruker Match System NMR
Sample Tubes from Norell Inc., Landisville, NJ): 10 cm in length and 3.43 mm inner
diameter. The walls of the tube were 0.41 mm thick. The tube was fixed to lie horizontally
in a water tank for imaging and positioned so that the B0 field lay transverse to the tube's
long axis. The tube's center slice was imaged in coronal view at 3 T with an imaging
resolution of 256 × 256 pixels, a 180mm FOV (field of view), a slice thickness of 7 mm and
a repetition time, TR=100 ms. Using 10 averages, the total scan time was 4.25 minutes. The
phase maps and B0 maps are shown in Figures 2 and 3 for the Feridex contrast agent, where
TE=2.83 ms for the phase map and ΔTE=0.9 ms for the B0 map. The B0 map was corrected
for edge effects and shimming by taking a second B0 map in the absence of the tube and
identical imaging parameters including the same shimming fields. The second B0 map was
then subtracted from that due to the tube. The original result before correction is shown in
Figure 2 for the Feridex agent. The corrected B0 map is shown in Figure 3. For the MRI
measurements, both contrast agents were examined in their undiluted concentrations to
ensure maximum SNR in the resulting images. An identical procedure was employed to
obtain a similar result for the Magnevist agent. Simplistic phase unwrapping (Matlab
“unwrap” command) was employed but was found to be insufficient due to the complex
spatial dependence of the phase in Figures 2 and 3. By utilizing the tolerance parameter of
the Matlab “unwrap” command, the regions where no phase wrapping occurred were
identified.
Theoretical solutions for infinitely long cylinders
The theoretical solution for the magnetic fields associated with an NMR vial placed
transverse to the B0 field is analytically tractable assuming that the cylinder is infinite in
length. This is a more than adequate assumption for the finite-length cylinders used in
subsequent experiments where the length:inner diameter ratio was 29. For the case of the
paramagnetic gadolinium agents, the problem is a two-dimensional, three-region problem
where the magnetic susceptibilities of the three regions are χ1, χ2 and χ3. In this work, χ1
corresponds to the region of contrast agent (0 < r < R1), χ2 is the glass vial (R1 < r < R2) and
χ3 is the water region (r > R3), r is the radial displacement from the center of the vial and R1
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and R2 are the inner and outer radii of the long glass tube. For the case of the SPIO Feridex
agent, the region of the contrast agent (0 < r < R1) is considered to have a spatially-invariant
magnetization which is colinear with B0 and has magnitude Ms. This case is explored later.
For an infinitely long vial, simplification arises with the consideration of a two-dimensional
cylindrical coordinate set (r, Ø) and the definition of a transverse magnetic scalar potential,
Ψ(r, Ø), for a non-conducting medium such that ▽ × H = O and H = − ▽Ψ. In addition, ▽ ·
B = μ0 H · (H + M = 0. For region 1 (0 < r < R1) in this work, ▽ · H = 0 whether (i) M = χH
where χ = χ1 is taken to be the spatially uniform magnetic susceptibility of the gadolinium
contrast agent, or (ii) |M| = Ms where Ms is the resulting magnetization of the contrast agent
which is a function of and parallel to H as given by the Langevin relation for the SPIO
contrast agent at 3 T. In practice, SPIO contrast agents are magnetically saturated at high
fields so Ms is virtually independent of H at 3 T. The relation ▽ · H = 0 is also true in
regions 2 and 3 since these are linearly magnetizable regions with magnetic susceptibilities
of χ2 and χ3 respectively. Under these conditions, Ψ obeys Laplace's equation, given in (1).
Ψ is independent of z for infinitely long cylinders.
(1)
Eq. (1) has solutions in a cylindrically symmetric geometry as given by Eq. (2) where C1,
D1, C2, D2, C3 and D3 are constants to be evaluated by means of boundary conditions at r =
R1 and R2.
(2)
Since Ψ cannot yield infinite field solutions at r = 0, we conclude that D1 The components
of H might be written using the gradient operator in cylindrical coordinates, as in Eq. (3),
where ir and iφ are unit vectors in the two-dimensional cylindrical coordinate system.
(3)
The corresponding components of the B field solutions are given by Eq. (4) for a linearly
magnetizable region 1.
(4)
The constants are solved by considering the boundary conditions as follows:
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(5)
Applying these boundary conditions to Eqs. (3) and (4) yields the following solutions for C1
through D3 as given in Table 1(a).
Substitution into (3) and (4) yields the complete solution for the H and B fields. In practice,
MRI only measures changes in the local field which are parallel to the large B0 field.
Therefore, the imaged change in local magnetic field in the third region (r > R2) is
effectively ΔBx, given by (7) for an x-directed B0 field. Defining the main field to be x rather
than z directed is unconventional in MRI but, in this analysis, it allows us to retain the usual
nomenclature in the cylindrical coordinate system characterized by {r, Ø, z}. In the cases of
both the gadolinium and SPIO agents, the water region (outside of the NMR vial) was
assumed to have a diamagnetic susceptibility of χ3 = −9.06 × 10−6 and the NMR glass vial,
a diamagnetic susceptibility of χ2 = −9.77 × 10−6, following the work of Bowen et al. (14).
The theoretical solution of (7) for the gadolinium agent, Magnevist, is plotted in Figure 6(a).
For this work, R1, is 1.715 mm, corresponding to the inner radius of the vials, R2 = 2.125
mm and r represents the cylindrical radial distance measured from the vial's axial center.
The main field intensity in A/m is denoted H0ix and φ = arctan (y/x).
(6)
(7)
The expression given by (7), which is the exact solution for ΔBx when r > R2, differs from
the approximate solution supplied by Chu et al. (13) and subsequently used by Bowen et al.
(14). It is the expression of (7) which is used in this work.
It should be apparent that for either a partially or fully magnetically saturated fluid, such as
the SPIO Feridex solutions considered in this work, a more general formulation is required
where the SPIO magnetization is Ms (as described by the Langevin function but, in practice,
a constant at 3 T) in the inner region (0 < r < R1) rather than the linear magnetization
susceptibility described by χ1. In this case, the revised B field for (0 < r < R1) is given by (8)
while the H field solution of (3) remains unchanged. The subsequently revised solutions for
C1 through D3 are as given by Table 1(b). The theoretical solution of (7) for the SPIO agent,
Feridex, is plotted in Figure 4(a).
(8)
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The change in ΔBx for r > R2 is again given by (7) but where D3 is now revised as indicated
in Table 1(b).
The matching of the simulated theoretical field with the experimental results from the MRI
was achieved by manually overlapping of the vial's outline in each case for the slice at the
vial's axial center. The resultant least-squares fitting was achieved with Matlab (The
MathWorks Corp., Natick, MA). Clearly some phase wrapping occurs in the region around
the tube as the field varies too rapidly to be captured accurately by the field map. This
means that the recorded field immediately surrounding the tube itself is severely distorted
from the actual value. However, the dipole fields are closely matched in areas which do not
suffer from phase wrapping (e.g., >2 cm from the vial's axial center).
RESULTS
The results of Figure 4 for the Feridex contrast agent were compared for the line of
maximum field variation in the coronal plane (indicated by the black solid line). The results
are shown in Figure 5 where the blue solid line indicates the measured result for the change
in local Larmor frequency in the water region using MRI, the red line represents a least-
squares fit of the MRI result assuming Ms = 80 Am2/kg Fe and the black dashed line
represents the result based on the VSM measurement of Ms = 82 Am2/kg Fe. As usual, the
Larmor frequency is related to the local magnetic field by the gyromagnetic ratio with a
value of 42.58 MHz/T for the 1H proton. Since the simulated dipole distribution shown in
Figure 4(a) represents the change in the x component of the B0 field rather than the
magnitude of the magnetic field, the distribution is quadrapolar rather than dipolar as given
by Equation 7 for an infinite cylinder in an x-directed field with finite wall thickness.
Using an identical procedure to that outlined to obtain the results of Figure 4, the B0 and
phase maps were obtained for the Gd-based contrast agent, Magnevist. The theoretical
results from Matlab (using the value for the mass susceptibility estimated from the VSM
results to be 2.06 × 10−6 m3/kg Gd) and B0 map at 3 T are shown in Figure 6. The results in
Figure 6 are compared along the line of maximum field variation in the coronal plane, as
was the case for the Feridex results. The results are shown in Figure 7 where the blue solid
line indicates the measured result for the change in local Larmor frequency using MRI, the
red line represents a least-squares fit of the MRI result assuming χm = 1.96 × 10−6 m3/kg Gd
and the black dashed line represents the result from the VSM measurement of χm = 2.06 ×
10−6 m3/kg Gd. It should be noted that the mass susceptibility, χm in m3/kg, is related to the
absolute susceptibility, χ (unitless), by the concentration of the magnetic material in the fluid
which was 78 kg Gd/m3.
DISCUSSION
The results for the saturation magnetization of Feridex contrast agent are compared in Table
2 using three different methods. These are (i) the VSM measurements which yielded a result
of 82 Am2/kg Fe at 1.2 T, (ii) the fitted MRI measurement which yielded a value of 80 Am2/
kg Fe at 3 T and (iii) the published result of Jung et al. who cite a result of 93.6 Am2/kg Fe
at 5 T. For the results detailed here, VSM and MRI measurements coincide within 2.5% for
Feridex and 5% for Magnevist.
One possible reason for the slight differences between the values of this work and previous
result is possible variations in the formulations investigated by earlier workers (11,12) and
this current work which uses commercially available solutions. An explanation for the
discrepancy between the MRI and VSM results is possible misalignment between the
theoretical and experimental phase maps. This would result in an inaccurate fit of the
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experimental data (for example, if datapoints closer to the vial tend to suffer more from
uncompensated edge effects, this is not reflected in the least-squares fit) and a misalignment
between the theoretical result and the MRI measurement (meaning that pixels were not
exactly matched in space and therefore introducing an error in the predicted value for the
saturation magnetization).
The results for the mass susceptibility of Magnevist contrast agent is compared in Table 3.
The comments of the previous paragraph are again applicable. A final note on the Magnevist
MRI results is regarding the increased noise in the signal of Figure 7 compared to the
Feridex MRI result in Figure 5. This perceived increase in noise is only due to the decreased
scale of the local Larmor frequency shown in the Magnevist result rather than due to any
increase in the noise inherent to the experiment. The SNR might be improved by increasing
the slice thickness and the image FOV albeit leading to the inevitable increase in cylinder
end-effects and loss in spatial resolution.
While T1 and T2 are the usual parameters most critical to MR image contrast, there are
clinical situations where a measure of the absolute magnetization of the contrast agent is
desirable. These include susceptibility-weighted imaging (15,16) where the local magnetic
field is distorted by the magnetization associated with the contrast agent. While the work
outlined here details the in vitro analysis of the magnetization associated with MRI contrast
agents, the work might be extended to in vivo studies by examining the flow in long blood
vessels where a measurable component of the B0 field lies perpendicular to the vessel.
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Figure 1.
Measured magnetization using a VSM for (a) Feridex and (b) Magnevist MRI contrast
agents. The units of magnetic moment are (a) Am2/kg Fe for Feridex and (b) Am2/kg Gd for
Magnevist.
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Figure 2.
The measured phase map is shown for the center coronal slice of a tube of Feridex agent
surrounded by water. The phase map only shows the net field component along the x-axis,
i.e., Bx. The B0 field is left to right (x-directed) and has a value of 3 T.
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Figure 3.
The B0 map is shown for the center coronal slice of a tube of Feridex agent surrounded by
water. Edge and shim effects were eliminated by means of a subtraction of the B0 maps
measured in the absence of any tube.
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Figure 4.
Comparing Feridex contrast agent (a) theoretical results from Eq. (7) and (b) B0 maps from
the scanner at 3 T. The black line indicates the line of maximum field variation.
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Figure 5.
Comparing experimental results for Feridex contrast agent from the MRI (blue), results from
the VSM at 1.2 T (black dashed) and theoretical results from Comsol Multiphysics (red)
based on a least-squares fit of the MRI data for the change in local Larmor frequency due to
the SPIO agent, Feridex at 3 T. The x axis corresponds to the solid black lines in Figure 4.
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Figure 6.
Comparing for Magnevist contrast agent (a) theoetical results from Eq. (7) and (b) B0 maps
from the MRI at 3 T for Magnevist contrast agent.
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Figure 7.
Comparing experimental results for Magnevist from the MRI (blue), extraopolated results
from the VSM at 1.2 T (black dashed) and theoretical results from Eq. (7) (red) based on a
least-squares fit of the MRI data for the change in local Larmor frequency at 3 T. The x axis
corresponds to the solid black lines in Figure 6.
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Table 1
Table of Coefficients
Coefficient (a) Gadolinium agent (M = χ1H) (b)SPIO agent (M = Ms H∣ H ∣ )
C1
− 4H0R22(1 + χ2)(1 + χ3)
R12(χ1 − χ2)(χ2 − χ3) + R22(2 + χ1 + χ2)(2 + χ2 + χ3)
4H0R22(1 + χ2)(1 + χ3) − Ms(R12(χ2 − χ3) + R22(2 + χ2 + χ3))
R12χ2(χ2 − χ3) − R22(2 + χ2)(2 + χ2 + χ3)
D1 0 0
C2
− 2H0R22(2 + χ1 + χ2)(1 + χ3)
R12(χ1 − χ2)(χ2 − χ3) + R22(2 + χ1 + χ2)(2 + χ2 + χ3)
−
MsR12(χ2 − χ3) − 2H0R22(2 + χ2)(1 + χ3)
R12χ2(χ2 − χ3) − R22(2 + χ2)(2 + χ2 + χ3)
D2
2H0R12R22(χ1 − χ2)(1 + χ3)
R12(χ1 − χ2)(χ2 − χ3) + R22(2 + χ1 + χ2)(2 + χ2 + χ3)
−
R12R22( − 2H0χ2(1 + χ3) + Ms(2 + χ2 + χ3))
R12χ2(χ2 − χ3) − R22(2 + χ2)(2 + χ2 + χ3)
C3 − H 0 − H 0
D3
H0R22(R22(2 + χ1 + χ2)(χ2 − χ3) + R12((χ1 − χ2)(2 + χ2 + χ3)))
R12(χ1 − χ2)(χ2 − χ3) + R22(2 + χ1 + χ2)(2 + χ2 + χ3)
−
R22(2MsR12(1 + χ2) − H0( − R22(2 + χ2)(χ2 − χ3) + R12χ2(2 + χ2 + χ3)))
R12χ2(χ2 − χ3) − R22(2 + χ2)(2 + χ2 + χ3)
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Table 2
Comparison of Feridex Results for Ms
VSM Measurement Fitted MRI Result Published Result (12)
82Am2/kg Fe 80 Am2/kg Fe 93.6 ± 1.6 Am2/kg Fe
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Table 3
Comparison of Magnevist Results for xm
VSM Measurement Fitted MRI Result Published Result (11)
2.06 × 10−6m3/kg Gd 1.96 × 10−6m3/kg Gd 2.13 ± .08 × 10−6m3/kg Gd
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